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28

Abstract

29

There is a need for improved understanding of how different cerebrovascular reactivity (CVR)

30

protocols affect vascular cross-sectional area (CSA) when measures of vascular CSA are not

31

feasible. In human participants, we delivered ~±4mmHg end-tidal partial pressure of CO2

32

(PETCO2) relative to baseline through controlled delivery, and measured changes in middle

33

cerebral artery (MCA) cross-sectional area (CSA; magnetic resonance imaging (7 Tesla MRI)),

34

blood velocity (transcranial Doppler and Phase contrast MRI), and calculated CVR based on

35

steady-state versus a ramp protocol during two protocols: a 3-minute steady-state (+4mmHg

36

PETCO2) and a ramp (delta of -3 to +4mmHg of PETCO2). We observed that 1) the MCA did not

37

dilate during the ramp protocol, but did dilate during steady-state hypercapnia, and 2) MCA blood

38

velocity CVR was similar between ramp and steady-state hypercapnia protocols, although

39

calculated MCA blood flow CVR was greater during steady-state hypercapnia than during ramp,

40

the discrepancy due to MCA CSA changes during steady-state hypercapnia. Due to the ability to

41

achieve similar levels of MCA blood velocity CVR as steady-state hypercapnia, the lack of change

42

in MCA cross-sectional area, and the minimal expected change in blood pressure, we propose that

43

a ramp model, across a delta of ~-3 to +4mmHg PETCO2, may provide one alternative approach

44

to collecting CVR measures in young adults with TCD when CSA measures are not feasible.

45
46
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Introduction

53

Cerebrovascular reactivity (CVR) studies assess changes in cerebral blood flow to a known

54

vasoreactive stimulus (e.g., changes in end-tidal partial pressure of CO2; PETCO2). Measures of

55

CVR are important because attenuated CVR may reflect preclinical vascular pathophysiology and

56

an increased risk of mortality independent from cardiovascular risk factors or stroke incidence (1).

57

The most commonly used technique for CVR measures in humans, transcranial Doppler (TCD)

58

ultrasonography, provides an index of vascular blood flow changes (i.e., blood velocity) because

59

the vascular cross-sectional area (CSA) values required for blood flow calculations (i.e., the

60

product of CSA and blood velocity) are not collected with TCD. Thus, an assumption of an

61

unchanging CSA is typically accepted, raising concern if changes in CSA do occur (2). To

62

circumvent issues related to TCD measures of CVR, some research groups measure all four brain-

63

supply (i.e., carotid and vertebral) arteries outside of the brain (3), or use expensive neuroimaging

64

approaches (4,5).

65

An additional concern regarding quantification of CVR is the potential for changes in central

66

hemodynamics during hypercapnia (elevated PETCO2) that could elevate cerebral blood flow due

67

to changes in cardiac output (6) and blood pressure (6,7) and not directly due to cerebrovascular

68

dilation (7). Another complicating factor in quantifying CVR between groups is potential variation

69

in large cerebral artery reactivity, particularly when comparing age differences (8). As an example,

70

our group’s previous work showed that compared to younger adults, older adults exhibited

71

attenuated changes in large cerebral artery CSA in response to steady-state hypercapnia (9).

72

However, obtaining cerebral artery CSA data requires access to costly MRI or CT systems. We

73

aim to understand protocol designs that provide accurate CVR estimates when using TCD

74

methods. The “ideal” velocity based CVR protocols conducted using TCD would require: 1)

75

minimal CSA changes by conducting CVR protocols that result in negligible change in CSA, and

76

2) minimal influence of confounding variables such as blood pressure.

77

In the current study, we tested the hypothesis that a ramp (i.e., linear) CVR protocol within the ±5

78

mmHg range of relative changes in PETCO2 would provide minimal changes in CSA while still

79

replicating CVR outcomes from the more standard steady-state hypercapnia CVR protocol. Our

80

rationale for this range of relative changes in PETCO2 comes from the emerging knowledge of a

81

sigmoidal change in MCA CSA, with minimal changes in hypercapnia, within the -5 to +5 mmHg
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from resting PETCO2 (10). We chose a ramp-style CVR protocol to compare to CVR measures

83

from a steady-state hypercapnia protocol (0 to ~5 mmHg) because: 1) the ramp protocol is a well-

84

established protocol for CVR measures (7,11,12), and 2) existing means for calculating CVR from

85

standard steady-state protocols use linear slope methods which simply reduce to a ramp design.

86

We acknowledge that the ramp protocol within the ~∆±5 mmHg from baseline PETCO2 range may

87

potentially affect vascular dilation differently than a steady-state hypercapnia protocol as the

88

hypocapnia portion preceding hypercapnia may blunt blood velocity CVR (13). A sub-analysis in

89

our earlier work, however, indicated that order of condition did not affect CSA reactivity in young

90

adults (4). Additionally, existing methods primarily focus on velocity-based CVR without

91

considering CSA, and we wanted to design a CVR protocol that minimized CSA changes (even if

92

it involved hypocapnia) and blood pressure changes while retaining its ability to elevate cerebral

93

blood flow (i.e., changing blood velocity). Other models can be considered but we want to test the

94

ramp protocol as one example of alternative CVR designs that may elicit negligible CSA and BP

95

changes when measuring blood velocity CVR using TCD.

96

To achieve the high temporal resolution of the MCA CSA for the required study, we developed a

97

dynamic anatomical imaging sequence with high-temporal and spatial resolution to capture MCA

98

CSA changes every 14 seconds throughout each vasoreactivity protocol (~±∆4 mmHg) using 7T

99

magnetic resonance imaging. Our objectives were to assess whether between steady-state and ramp

100

protocols: 1) the MCA CSA increased compared to baseline, 2) blood pressure remained stable

101

throughout duration of the protocol, and 3) MCA blood velocity (via TCD alone), and calculated

102

flow vasoreactivity were similar.

Materials and Methods

103
104

Participants

105

All testing was conducted at the Centre for Functional and Metabolic Mapping at The University

106

of Western Ontario. The Human Subjects Research Ethics Board at the University of Western

107

Ontario (London, Ontario, Canada) approved the experiment protocols herein. Informed consent

108

from 12 healthy subjects (19-25 years of age; 6 males) was obtained prior to scanning. A sample

109

size calculation was based off of our previous work with blood velocity reactivity measured with
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TCD during steady-state hypercapnia (4). Specifically, for a within-subject design, with a Cohen’s

111

d of 1.02, alpha level of significance of 0.05, and statistical power of 0.80, we calculated a sample

112

size of 10 and recruited 12 individuals due to our laboratory’s expected attrition rate of 10-12%

113

with our neuroimaging studies. Participants were ineligible if they were smokers, pregnant, or had

114

any of the following conditions: Raynaud’s disease, respiratory illnesses, diabetes, claustrophobia,

115

history of psychosis, eating disorders, manic or bipolar disorder, major psychiatric conditions, or

116

dependence on alcohol or drugs.

117

Procedure and data recording

118

Testing was completed between 10am – 2pm. Participants refrained from exercise, alcohol, drugs,

119

and caffeine within 12 hours prior to testing. We used TCD and MRI to assess the cerebral

120

vasoreactivity in response to steady-state (three minutes) bouts of hypercapnia (HC), and a ramp

121

protocol from hypocapnia to hypercapnia (four minutes) (Fig. 1).

Figure 1 – Experimental protocol schematic. Left: Experimental setup displaying real-time data
collection for both transcranial Doppler and MRI sessions. Right, panel a: Ramp hypercapnia protocol
with a desired target range of -5 to +5 mmHg from baseline PETCO2 and a duration of 240 seconds.
Right, panel b: Steady-state hypercapnia (SSHC) protocol with a target range of +5 mmHg from baseline
PETCO2 and a duration of 180 seconds. Protocols were executed using the RespirAct™ device with
preset protocols programmed with the desired PETCO2 values.

122

Steady-state and ramp protocols were each conducted twice, once for each of the TCD and MRI

123

portions of the testing sessions and the order of TCD and MRI trials was randomized across

124

participants. Unfortunately, we were unable to randomize the order of CVR protocols as it was

125

difficult to stop and restart the RespirAct™ (Thornhill Research Inc., Toronto, Ontario, Canada)
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without doing extensive recalibration. The desired ventilatory rate was set to 12 breaths/min using

127

a visual metronome for each session and was projected on a screen during the MRI scan. Our goal

128

was to have the protocols fall within the ±5 mmHg from baseline PETCO2 range. Following a

129

familiarization period of four minutes, the order and duration of protocols occurred as follows: 1)

130

baseline (1 minute), 2) steady-state hypercapnia (target was +5 mmHg, although only reached

131

~+4mmHg; three minutes), 3) recovery (2 minutes) 4) baseline (1 minute), 5) -5 mmHg PETCO2

132

hypocapnia (brief hyperventilation; target was +5mmHg, although only reached ~ -3mmHg) 30

133

seconds), 6) incremental increase (ramp) from ~ -3 mmHg hypocapnia to ~ +4 mmHg relative

134

PETCO2 hypercapnia (four minutes), 7) recovery (two minutes).

135

Manipulating target PETCO2 stimulus

136

Prior to the MRI scan, participants were fitted with a facemask attached to the RespirAct™ system,

137

a modified sequential gas delivery breathing circuit(13) was used to clamp PETCO2 levels at the

138

desired +5 or -5 mmHg (depending on protocol). Breathing rate and tidal volumes were calibrated

139

prior to starting the breathing sequence.

140

MCA blood velocity and systemic blood pressure

141

While supine, continuous beat-to-beat arterial blood pressure was monitored using a Finapres®

142

Finometer system, where a finger cuff was placed on the middle phalange of the third finger, and

143

the finger blood pressure was calibrated with an upper arm cuff (Finapres® Medical Systems,

144

Amsterdam, Netherlands). The MCA was insonated with a 2 MHz ultrasound probe placed at the

145

temporal window and the peak blood flow velocity envelope was collected using the Neurovision

146

TCD System (Multigon Industries Inc., NY, USA). All analog data were sampled at 1000 Hz using

147

the PowerLab data acquisition system (ADInstruments, Dunedin, Otago, New Zealand).

148

MCA vascular diameter and blood velocity during MRI

149

A 7 Tesla MRI (Siemens, Magnetom Step 2.3, Erlangen, Germany) system was used to acquire

150

the following datasets: 1) 3D time-of-flight (TOF) with 0.8mm isotropic voxel resolution, echo

151

time (TE)/ repetition time (TR) = 2.59ms/18ms, flip angle (FA) = 15⁰, bandwidth (BW) =

152

203Hz/pxl; 2) single-slice 2D phase contrast (PC-MRI) for MCA M1 segment blood velocity, with

153

a voxel resolution of 0.3×0.3×1.4mm3, TE/TR = 7.72ms/24.3ms, four averages, FA = 20⁰,

154

velocity-encoding (Venc) = 100cm/s and BW = 250Hz/pxl. During PC-MRI, a Venc value of
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100cm/s was used for all subjects, except for one hypercapnic case, where a Venc of 130cm/s was

156

used to avoid wrap-around artifact; and 3) cross-sectional area of the MCA M1 segment using

157

single-slice 2D turbo spin-echo T1-weighted imaging with 0.5×0.5×1.5 mm3, TE/TR = 12/750ms,

158

BW = 270Hz/pxl, with an acquisition time of 13-14 seconds. The TOF data were used to locate a

159

straight segment on the right MCA M1 segment with the least curvature. The single-slice PC-MRI

160

and T1-weighted data were then acquired orthogonally to the axis of the selected MCA segment.

161

The T1-weighted data were acquired sequentially in order to monitor the changes in MCA

162

diameter.

163

Data analysis

164

Data analysis was carried out offline using custom R scripts (RStudio; v. 2020), GraphPad (V.8),

165

and LabChart Pro (v.8, ADInstruments, Dunedin, Otago, New Zealand).

166

Transcranial Doppler ultrasound

167

The MCA blood velocity (via TCD) and MAP were averaged beat-by-beat over the cardiac cycle

168

then were exported at 5 Hz sampling frequency and saved as text files (LabChart Pro v.8,

169

ADInstruments, Dunedin, Otago, New Zealand). During the TCD collection phase of testing, start

170

and end times of each event throughout the experimental breathing protocol were chronicled by

171

comments added in the LabChart file.

172

Magnetic resonance imaging (MRI; 7 Tesla)

173

During the MRI collection phase of testing, start and end times of each event were chronicled

174

based on the time associated with the desired PETCO2 on the exported RespirAct™ data file. For

175

the T1-weighted anatomical MCA images, start and end times for each protocol event were

176

recorded based off the MRI console such that images were lined up offline based on the DICOM

177

image acquisition time. The brain anatomical images were imported into a DICOM reader, OsiriX

178

software (Pixmeo©, Bernex, Switzerland), and MCA cross-sectional area (CSA) was measured by

179

a blinded rater (MK) and compared against an expert rater (BKA).

180

The PC-MRI data were acquired for 30 seconds at baseline and within a ~70-second window

181

following 50-60 seconds from the start of steady-state hypercapnia (as noted on Fig 4, panel J with

182

the PC-MRI text bar). The MCA blood velocity measurements during the MRI session were

183

obtained from PC-MRI data by manually contouring a region-of-interest (ROI) inside the MCA
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lumen. The contours were drawn using the software, signal processing in NMR (SPIN-Research,

185

MR Innovations Inc., Detroit, MI, USA). Care was taken to avoid any peripheral voxels within the

186

MCA lumen. The magnitude PC-MRI data was used to locate the MCA lumen. The peak velocities

187

were calculated for each subject for baseline and hypercapnic states.

188

Data extraction

189

The LabChart text files, the TCD and MRI session RespirAct™ breath-by-breath PETCO2 values,

190

and the measured CSA were aligned using RStudio (v. 2020) (14) for data extraction from specific

191

epochs as indicated by the event comments in each file. The “print” function in the “magicfor”

192

package in R (15) was used to extract data with each loop iteration for each participant, and

193

variables of interest were exported as .csv files and imported to GraphPad Prism for graphing and

194

analysis.

195

Steady-state condition time courses were baseline corrected by subtracting mean baseline value (-

196

30 to 0 seconds of time window of interest) for each respective variable and plotted as delta values

197

(Fig. 4). For the baselines and steady-state condition, the data were extracted from the following

198

sections within the protocol: 1) 30 seconds baseline prior to onset of hypocapnia prior to the ramp

199

protocol and 2) 30 seconds baseline prior to steady-state hypercapnia, and 3) 60 seconds at the end

200

of steady-state hypercapnia. The ramp slope analysis included the entire hypocapnic to

201

hypercapnic incremental data (see below).

202

Ramp protocol

203

The target PETCO2 and ramp protocol schematic is shown in Fig. 1, panel a. The target ventilation

204

rate was 12 breaths/minute and participants were coached using a visual metronome. In order to

205

equalize the spacing on the time axis when plotting the achieved PETCO2 data, the PETCO2 and

206

corresponding time vectors were resampled to a fixed 12 breaths/minute sampling rate using the

207

base R “approx” function in RStudio. Thus, two time vectors were created: 1) a target time vector

208

that is based off of a 12 breath/minute ventilation rate and 2) a “fixed” time vector that is based

209

off of resampling each participants data to meet the target time vector. The inter-individual

210

differences for the “fixed” time vector are indicated by horizontal error bars (mean ± S.D.; Fig. 3,

211

panels a-b), and the data are plotted and averaged for all participants along the target 12

212

breaths/minute time vector.
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MCA blood velocity and systemic MAP data (in 0.2 second increments or 5 MHz sampling

214

frequency) were plotted from the hypocapnic state to the hypercapnic state during the ramp

215

protocol and averaged at each time point across the 12 participants (Fig. 3 panels c-d). Similarly,

216

the CSA values along the ramp protocol were averaged for each time point across participants

217

(Fig. 3 panel e). Although our goal was to collect 4 minutes of ramp data, the transition point from

218

the nadir of hypocapnia to start of ramp was different for each person and it generally took

219

approximately 2 breaths (~12 seconds) to sync with the desired PETCO2 for the hypercapnic ramp.

220

Thus, to ensure the same number of samples (n=12) for each time point along the ramp protocol,

221

we only extracted the last 228 seconds of ramp data for all participants (instead of the full 240

222

seconds).

223

Steady-state protocol

224

Data extraction and organization were similar to the ramp protocol except data extraction occurred

225

between the start and end of the three-minute steady-state hypercapnia stimulus. As previously

226

mentioned, the PC-MRI data acquisition commenced 50-60 seconds from start of steady-state

227

hypercapnia. Thus, the continuous T1-anatomical MCA CSA scans were interrupted to allow for

228

PC-MRI imaging (correlation with TCD measures of blood velocity are shown in Fig. 2). PC-MRI

229

data were collected for 11 out of our 12 participants. As there were shifts in PC-MRI data collection

230

start and end times across participants, the upper and lower bounds of these time points are

231

indicated under the “PC-MRI” text bar on Fig. 3 (panel e, bottom row) to indicate to the reader

232

that the mean and S.D. for CSA values in this portion of the protocol do not include all 11

233

participants (i.e., n < 11) for the CSA data.

234

The averaged raw values for the 30 seconds baseline (prior to start of stead-state hypercapnia;

235

indicated as B on x-axis in Fig. 4) and last minute of steady-state hypercapnia (indicated as SSHC

236

on x-axis on Fig. 4) are shown in Fig. 4 for PETCO2, MCA blood velocity (via TCD) and mean

237

arterial pressure (MAP) during the TCD session and the PETCO2, MCA blood velocity (via PC-

238

MRI) and MCA CSA during the MRI session.

239

MCA blood velocity reactivity calculations

240

The ramp and steady-state hypercapnia MCA blood velocity cerebrovascular reactivity (CVR)

241

measures are shown in Fig. 5 panel a. For the ramp protocol, the MCA blood velocity slope (Fig.
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3 panel c) and the PETCO2 (for TCD session; Fig. 3 panel a) slope were calculated for each person

243

and the MCA blood velocity CVR was calculated as:

244

MCA Blood Velocity CVR =

MCA Blood Velocity Slope
PETCO2 Slope

(1)

245

For the steady-state hypercapnia protocol, the difference between the average baseline before start

246

of hypercapnia and the average of the last minute of hypercapnia (i.e., the difference between the

247

SSHC and B conditions in Fig. 4) were calculated. For each individual, the MCA blood velocity

248

CVR during the steady-state hypercapnia condition was then calculated as:

249

MCA Blood Velocity CVR =

∆MCA Blood Velocity
∆PETCO2

(2)

250

MCA blood flow reactivity calculations

251

The ramp and steady-state hypercapnia MCA blood flow CVR measures are shown in Fig. 5 panel

252

b. For the ramp protocol, the MCA blood velocity was sectioned into 14 second averages

253

corresponding to each CSA image along the ramp protocol. Each of these averaged MCA blood

254

velocity values were multiplied by the corresponding CSA for the given time point to calculate

255

blood flow at 14 second increments along the ramp protocol. To keep it consistent with the MCA

256

blood velocity CVR measures, the PETCO2 slopes from the TCD sessions were used as the

257

denominator during CVR calculations. The slopes were calculated for each person and the MCA

258

blood flow CVR was calculated for each individual as:

259

MCA Blood Flow CVR =

MCA Blood Flow Slope
PETCO2 Slope

(3)

260

Finally, to compare the MCA blood velocity CVR values and the MCA blood flow CVR values

261

calculated during the steady-state hypercapnia protocol, the percentage change from baseline for

262

each of the MCA blood velocity or blood flow were calculated (Fig. 5, panel c).

263

Statistical summary

264

Inter-rater variability was assessed using Bland-Altman analysis for 45 randomly selected images.

265

Pearson’s correlation coefficient was used to test the correlation for inter-modality (TCD vs. PC-

266

MRI; Fig. 2) MCA blood velocity measures for both baseline and steady-state hypercapnia states

267

(P < 0.05 was considered to be statistically significant using a two-tailed test). In addition, linear

268

slope analysis was conducted to assess changes in PETCO2, MAP, MCA CSA, and MCA blood
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velocity variables during the ramp protocol. A probability level of P<0.05 indicates a non-zero

270

slope (the linear fits and p-values are labelled on Fig. 3 panels a-e). One-tailed paired t-tests were

271

conducted to compare variable responses during the steady-state hypercapnia condition versus

272

baseline (Fig. 4). Finally, to compare the MCA blood velocity CVR values and the MCA blood

273

flow CVR values calculated during the steady-state hypercapnia protocol, the percentage change

274

from baseline for each of the MCA blood velocity or blood flow was calculated (Fig. 5).

275

Results

276

Our CVR protocols with target PETCO2 are illustrated in Fig. 1. Inter-rater variability for CSA

277

measures using the Bland-Altman test indicated a bias of 0.15 ± 0.26 mm2 (mean ± S.D.; BKA -

278

MK) and 95% Limits of Agreement from -0.37 to 0.67 mm2 (45 randomly selected images). Inter-

279

modality (TCD vs PC-MRI) correlation for MCA blood velocity measures indicated a significant

280

Pearson correlation between baseline and steady-state hypercapnia for each modality (n = 11

281

participants, 22 pairs; r = 0.69, P < 0.05; Fig. 2).
Figure 2 – MCA blood velocity measure comparison
between TCD and PC-MRI. Correlation plot comparing
MCA blood velocity measured from transcranial Doppler
(TCD) and phase contrast magnetic resonance imaging
(PC-MRI). Baseline measures for both TCD and MRI
sessions and steady-state hypercapnia measure at the ~12 minute mark for PC-MRI and in the last minute of
steady-state hypercapnia for the TCD session for 22 pairs
(n=11; r = 0.69, P<0.05).

282

Slope analysis during the ramp protocol indicated significant slopes (P<0.05; Fig. 3 panels a - d)

283

for achieved ∆PETCO2 (mmHg) during TCD (Y = 0.033*X – 3.96; R2 = 0.88) and MRI (Y =

284

0.027*X – 2.54; R2 = 0.77) sessions, with corresponding slopes for ∆MCA blood velocity (cm/s;

285

Y = 0.13*X – 13.70; R2 = 0.59) and ∆MAP (mmHg; Y = 0.009*X – 0.38; R2 = 0.02). Although

286

significant, the slope for MAP during the ramp protocol indicated an average <2mmHg increase

287

throughout the protocol. The slope of the MCA CSA with time did not show a deviation from 0

288

across the ramp protocol (Fig. 3, panel E; Y = 0.0008*X – 0.057; R2 = 0.006).
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Figure 3 – Measured variables during the ramp and steady-state hypercapnia protocols. Ramp
protocol (228 seconds; top row) responses and steady-state hypercapnia (180 seconds; bottom row) for
delta changes in each variable from baseline levels are shown. Panel a: achieved PETCO2 for TCD
session, panel b: achieved PETCO2 for MRI session, panel c: MCA blood velocity in TCD session, panel
d: mean arterial pressure (MAP), and panel e: MCA cross-sectional area (CSA). The “PC-MRI” text on
panel e bottom row indicates the variable time window in which PC-MRI images were acquired and there
was an interruption in the consistent MCA CSA measurements. A 30 second baseline is shown for the
steady-state hypercapnia condition (bottom row) and hypercapnia is indicated by SSHC on x-axis with a
vertical line. Linear regressions (panels a-e top row) are shown for each variable in the ramp protocol
and a significant (non-zero; α level significance 0.05) slope is indicated by P < 0.05. N = 12 for all
variables with data presented as mean±S.D.

289

During the steady-state hypercapnia protocol, PETCO2 increased during steady-state hypercapnia

290

from baseline with a mean difference of 4.45 mmHg and 95% CI of 4.05 to 4.85 when using TCD

291

(44.3±3.1 vs. 39.9±2.9 mmHg, respectively; n=12, 𝜂p2=0.98, P<0.05; Fig. 4, panel a) and a mean

292

difference of 3.75 and 95% CI of 3.29 to 4.20 when using MRI (42.7±4.2 vs. 38.9±4.4 mmHg,

293

respectively; n=12, 𝜂p2=0.97, P<0.05; Fig. 4, panel b) sessions. Similarly, MCA blood velocity

294

increased with steady-state hypercapnia from baseline with a mean difference of 18 cm/s and 95%

295

CI of 13 to 24 cm/s in the TCD trial (104±29 vs. 86±24 cm/s, respectively; n=12, 𝜂p2=0.83, P<0.05;

296

Fig. 4, panel c) and a mean difference of 22 cm/s and 95% CI of 12 to 33 when using MRI (via

297

PC-MRI; 79±15 vs. 59±9 cm/s, respectively; n=11, 𝜂p2=0.70, P<0.05; Fig. 4 panel e) sessions, and

298

MCA CSA increased with a mean difference of 0.31 mm2 and 95% CI of -0.03 to 0.66 mm2 during

299

the MRI session (5.71±1.03 vs. 5.34±0.97 mm2, respectively; n=12, 𝜂p2=0.27, P<0.05; Fig. 4,

300

panel f). The mean difference in MAP between the last minute of steady-state hypercapnia and

301

baseline was 1.35 mmHg with a 95% CI of -0.82 to 3.5 mmHg which is most compatible with a

302

negligible change (90±8 vs. 89±8 mmHg, respectively; n=12; 𝜂p2=0.14, Fig. 4, panel e). Calculated

303

MCA blood flows (product of MCA blood velocity and CSA) increased from baseline to steady-
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state hypercapnia (267±54 vs. 348±78 ml/min, respectively; P<0.05, one-tailed paired t-test) with

305

a delta calculated blood flow of 81±30 ml/min.

Figure 4 – Baseline (B) and steady-state hypercapnia (SSHC) comparisons. Top row: Baseline (B)
and steady-state hypercapnia (SSHC) measures (n=12 except for panel d where n=11, mean±S.D.).
Where statistical significance occurs, p-values are indicated above data (ns = not significant; paired ttest; α level significance 0.05). Bottom row: Individual data points (n=12 except for panel d where n=11)
comparing baseline (B) to steady-state hypercapnia (SSHC) responses for the same variable in that
column as top row. The diagonal line (identity line) indicates where data would fall if there was no
measurable effect of SSHC from B. Data above the identity line indicates an increase in variable measure
with SSHC (from baseline; B).

306
307

The mean difference in MCA blood velocity-based measure of CVR between the ramp and steady-

308

state hypercapnia protocols was 0.18 with 95% CI of -0.59 to 0.96 which is most compatible with

309

a negligible effect of protocol on MCA blood velocity CVR (3.8±1.7 vs. 4.0±1.6 cm/s/mmHg,

310

respectively; n=12, two-tailed paired t-test, p=0.62, 𝜂p2=0.02, Fig. 5, panel a). The mean difference

311

in calculated MCA blood flow-based measure of CVR between the steady-state protocol and ramp

312

protocol was 5.0 with a 95% CI of 2.8 to 7.2 ml/min/mmHg and was statistically significant

313

(17.3±5.7 vs. 12.3±4.5 ml/min/mmHg, respectively; n=12, two-tailed t-test, P<0.05, 𝜂p2=0.70,

314

two-tailed t-test; Fig. 5, panel b). Similarly, when calculated as %change in MCA blood velocity

315

or MCA blood flow over the ∆PETCO2 during hypercapnia, the mean difference between MCA

316

blood flow CVR and MCA blood velocity CVR was (6.7±1.6 vs. 4.8±2.0 %/mmHg, respectively;

317

n = 12, P<0.05, one-tailed t-test). Finally, the %change of MCA blood flow was greater than the

318

%change of MCA blood velocity during the steady-state condition with a mean difference of 6.9

319

and 95% CI of -0.37 to 14.10 (29.8±8.2 vs. 21.5±9.6 %, respectively; n=12, P<0.05, one-tailed t-

320

test; Fig. 5, panel c).
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Figure 5 – Middle cerebral artery (MCA) blood velocity and flow reactivity across protocols
Top row: Calculated MCA blood velocity cerebrovascular reactivity (CVR) was not different
between ramp and steady-state hypercapnia (SSHC; panel a), while MCA blood flow CVR was
higher in SSHC compared to the ramp protocol (panel b). The percent change in calculated MCA
blood flow from baseline was higher than the percent change in MCA blood velocity from
baseline (panel c) with SSHC. Where statistical significance occurs, p-values are indicated above
data (ns = not significant; paired t-test; α level significance 0.05). N=12 for all variables with data
presented as mean±S.D. Bottom row: Individual data points (n=12) comparing ramp to steadystate hypercapnia (SSHC) responses (panels a-b) for the same variable in that column as top row
or MCA blood velocity to calculated MCA blood flow (panel c). The diagonal line (identity line)
indicates where data would fall if there was no measurable effect of protocol on CVR measures
(panels a-b) or effect of accounting for MCA CSA in flow calculations (compared to using MCAv
alone as an index of flow) when assessing %change of flow or MCAv during SSHC (panel c).
Data above the identity line indicates an increase in variable measure with SSHC (compared to
ramp; panels a-b) or higher %change in flow value for a given %change in MCAv.

321

Discussion

322

This is the first study to provide MCA CSA measures across ramp and steady-state hypercapnia

323

protocols, enabled by the ability to obtain MCA CSA measurements every 14 seconds with

324

prospective targeting of PETCO2. This approach enabled direct comparisons of the steady- state

325

versus a ramp protocols to establish valid CVR calculations using only measures of flow velocity.

326

The noteworthy findings of this study are that: 1) the MCA CSA did not change during the ramp

327

protocol with delta ~ -3 to +4 mmHg of PETCO2, but did increase with steady-state hypercapnia
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~ +4 mmHg of PETCO2), 2) blood pressure remained stable throughout duration of both ramp and

329

steady-state protocols, and 3) CVR measures based on MCA blood velocity cerebrovascular

330

reactivity was not different between ramp and steady-state protocols, but 4) MCA blood flow-

331

based CVR was greater during steady-state compared to the ramp protocol. Taken together, the

332

ramp protocol seems to result in similar CVR values as those observed in the steady-state protocol,

333

with the added advantage of having minimal and negligible effects on MCA CSA or MAP in the

334

face of moderate elevations in PETCO2.

335

Transcranial Doppler – MCA blood velocity & CVR measures

336

Often, CVR is characterized by the slope in the linear relationship between MCA blood velocity

337

and PETCO2 with respect to each variable’s relative change with time. The relationship between

338

arterial blood velocity and CO2 (16) is sigmoidal and both the range and starting point of PETCO2

339

affect the arterial blood velocity response to CO2 (17). Regan et al. (7) showed a lower MCA blood

340

velocity-based CVR during steady-state hypercapnia (∆PETCO2 of 10 mmHg) than during the

341

ramp hypercapnic protocol (-5 to +10 mmHg PETCO2). However, these ranges of PETCO2 can

342

elicit systemic hemodynamic effects (6) that can increase blood velocity changes independent of

343

cerebral vascular bed dilation. The current protocols used a lower dose of change in PETCO2 in

344

order to avoid the central hemodynamic and non-linear portions of the CVR curve.

345

MRI – MCA CSA & CVR measures

346

In the current study, PETCO2 values at the ends of both ramp and steady-state hypercapnia

347

protocols, and the calculated MCA blood velocity CVR measures, were not different between the

348

two protocols. Yet, the PETCO2 changes during the ramp protocol did not affect MCA CSA in

349

same the way that the steady-state hypercapnia protocol did. To quantify transient MCA CSA

350

measures, we developed an anatomical scan optimized to provide MCA images every 14 seconds.

351

This enabled imaging of the MCA during the dynamic stimuli such as the ramp protocol or onset

352

of the steady state protocol, as well as improving temporal sensitivity during the steady-state

353

model. To our knowledge, our 14 second anatomical scan of MCA CSA provides the highest level

354

of temporal resolution (i.e., shortest acquisition time) available when compared to existing

355

assessments of MCA CSA during steady-state hypercapnia protocols. From our current MCA CSA

356

findings, the MCA dilates under conditions where hypercapnia is elevated and sustained (i.e.

357

steady-state hypercapnia), rather than with brief exposure to elevated levels of PETCO2 (i.e., end
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of ramp protocol). This observation is supported by previous studies indicating a slow onset to

359

dilation in either the internal carotid artery (18) or the MCA (2), despite immediate changes in

360

MCA blood velocity that reflect downstream microvascular dilation to early hypercapnia.

361

This study supports previous MCA CSA findings in CVR studies that indicate MCA CSA dilates

362

after ~2 minutes of steady-state hypercapnia using 3T (2) and 7T MRI (4,5). Thus, CVR values

363

during the steady-state protocol indicated significant error when the MCA cross-sectional area was

364

not included. Specifically, we found that the %change in MCA blood velocity was lower than the

365

%change in MCA blood flow by ~7% (mean difference between these two measures). This value

366

is less than the 18% observed in work by Coverdale et al. (2). We believe the discrepancy in these

367

mean differences is due to the magnitude of hypercapnia achieved in each study, with ~ +∆4 mmHg

368

PETCO2 in the current study versus ~ +∆10 mmHg in PETCO2 for the study by Coverdale et al.

369

As well, there was a 5% increase in MAP in the study by Coverdale et al. (~4 mmHg) which was

370

greater than the increase in MAP for our study (~2 mmHg for ramp, and ~1 mmHg for steady-

371

state), a difference that may be attributed to the greater magnitude of the hypercapnia stimulus in

372

the the previous study. While mild variations in MAP are accounted for by autoregulatory

373

mechanisms such that MCA blood flow is sustained with negligible influence on MCA CSA,

374

autoregulation mechanisms are impaired during hypercapnia (19). Thus, we anticipate that the

375

higher the hypercapnic magnitude, the greater the risk that MAP will influence MCA CSA (and/or

376

blood velocity) augmenting any discrepancies between MCA blood velocity and calculated MCA

377

blood flow.

378

This is the first study to use a sequential gas delivery circuit (via the RespirAct™) when assessing

379

MCA CSA responses during hypercapnia, thereby more closely aligning partial pressure of arterial

380

and end-tidal CO2 levels (20). Interestingly, we achieved similar MCA blood flow CVR during

381

steady-state hypercapnia as previous work (2), and our MCA blood velocity CVR for both the

382

steady-state hypercapnia (2,21) and ramp protocol (7) were in agreement with previous studies.

383

As recommended by Regan et al. (7), when using a limited range of PETCO2 values during a

384

hypercapnic protocol, a linear approach to CVR analysis is appropriate.

385

Everything considered, a CVR measure based solely on TCD-acquired MCA blood velocity

386

measures during a ramp hypercapnia protocol seems to elicit a similar CVR outcome as the

387

commonly used steady-state protocol, but without the limitation of potential changes in MCA
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CSA. CVR outcome measures involve calculating MCA blood velocity changes for a given change

389

in PETCO2. Similarly, our study illustrates that even modest values of change in PETCO2 achieve

390

a comparable value of CVR at higher hypercapnic doses.

391

Methodological Considerations

392

Our overall target range for manipulating PETCO2 during the cerebrovascular reactivity was

393

between the -∆5 to +∆5 from baseline PETCO2 (10). While our findings support a lack of MCA

394

CSA changes during ramp protocols of -∆3 to +∆4 mmHg in PETCO2, we cannot make conclusive

395

remarks on MCA CSA changes during a ramp protocol of ±∆5mmHg in PETCO2. However, as

396

mentioned above, our values of ∆PETCO2 fell within our target ±∆5mmHg from baseline PETCO2

397

range, the CVR measures are consistent with previous studies where higher levels of PETCO2

398

were used, and we found negligible increases in MAP. Therefore, the modest level of PETCO2

399

achieved here appear to have achieved the major objectives. The ramp protocol designed for the

400

current study also achieved an optimal balance between stimulus and central hemodynamics. We

401

acknowledge however, that we did not account for the impact of the ~2 mmHg rise in MAP during

402

the ramp protocol, which we expect to be negligible in impacting MCA CSA.

403

Although we were unable to measure continuous blood pressure and MCA blood velocity during

404

the MRI trial, we measured blood velocity data during the MRI session via the PC-MRI sequence.

405

Testing of the TCD and MRI segments of the study were collected consecutively within a 2-hour

406

window with the order of tests varied across participants. The absolute values for MCA blood

407

velocities measured by PC-MRI were lower than our TCD measures, although we suspect this had

408

to do with our pre-set Venc value choice of 100 cm/s which may have cut off some of the higher

409

velocities. Our rationale for not choosing a higher Venc than 100 cm/s was the possibility of cutting

410

off lower velocity values during baseline. Regardless, the increase in MCA blood velocity during

411

hypercapnia (from baseline) were in agreement between the two techniques (TCD: ~∆18 cm/s and

412

PC-MRI: ~∆20 cm/s). Thus, we assume that the blood pressure responses during the TCD and

413

MRI sessions were similar as well.

414

Finally, the current results are delimited to young healthy adults Thus, additional studies are

415

needed to understand the effects of age, a group that demonstrates greater MAP responses to

416

hypercapnia and variable responses in CSA changes (9), or other differentiating conditions.
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Further, our study was conducted in the supine position, which is less replicable for CVR studies

418

than the seated position (22) and may explain some of the disparity of blood velocity measures for

419

some individuals between the two protocols: the supine posture is necessary for MRI studies.

420

Additional studies are required to address the impact of CSA changes and protocol model on

421

posture-dependent intra-subject variability so that reliable CVR protocols can be used to make

422

inferences on vascular health (e.g., inferred vascular dysfunction with reduced CVR). The current

423

data suggest that the ramp protocol might be useful in reducing inter-study variability.

424

Conclusions

425

A constant CSA during experimental vasoreactive challenges is essential to the reliability of TCD-

426

acquired blood velocity as a correlative index of blood flow changes. In this study, we showed

427

data that were most compatible with negligible change in MCA CSA from baseline during a graded

428

ramp hypercapnic protocol (± ~∆4 mmHg from baseline PETCO2). Similar to our previous work,

429

the MCA data align best with an interpretation of MCA dilation during a prolonged (3-minutes)

430

~∆4 mmHg in baseline PETCO2 period of hypercapnia, and confirmed the expected error in

431

%change of MCA blood velocity as an index of blood flow and in the calculated CVR when a

432

change in CSA is not considered (2). Combined, these data suggest that during transient changes

433

in PETCO2, as in the ramp protocol, the constant segment of the sigmoid may describe MCA CSA

434

changes with PETCO2, and any changes in blood velocity can reflect CBF. In summary, the ramp

435

protocol with ± ~∆4 mmHg from baseline PETCO2 appears to provide expected measures of CVR

436

where blood velocity should reflect blood flow patterns of change.
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